

Fill in this information to identify the case:

Debtor Name Amyris, Inc.

United States Bankruptcy Court for the: District of Delaware

Case number: 23-11131

Official Form 426

**Periodic Report Regarding Value, Operations, and Profitability of Entities
in Which the Debtor's Estate Holds a Substantial or Controlling Interest**

12/17

This is the *Periodic Report* as of **9/30/2023** on the value, operations, and profitability of those entities in which a Debtor holds, or two or more Debtors collectively hold, a substantial or controlling interest (a “Controlled Non-Debtor Entity”), as required by Bankruptcy Rule 2015.3. For purposes of this form, “Debtor” shall include the estate of such Debtor.

Amyris, Inc. holds a substantial or controlling interest in the following entities:

Name of Controlled Non-Debtor Entity	Interest of the Debtor	Tab #
<i>See Page 3 for entity listing</i>		

This *Periodic Report* contains separate reports (*Entity Reports*) on the value, operations, and profitability of each Controlled Non-Debtor Entity.

Each *Entity Report* consists of five exhibits.

Exhibit A contains the most recently available: balance sheet, statement of income (*loss*), statement of cash flows, and a statement of changes in shareholders’ or partners’ equity (*deficit*) for the period covered by the *Entity Report*, along with summarized footnotes.

Exhibit B describes the Controlled Non-Debtor Entity’s business operations.

Exhibit C describes claims between the Controlled Non-Debtor Entity and any other Controlled Non-Debtor Entity.

Exhibit D describes how federal, state or local taxes, and any tax attributes, refunds, or other benefits, have been allocated between or among the Controlled Non-Debtor Entity and any Debtor or any other Controlled Non-Debtor Entity and includes a copy of each tax sharing or tax allocation agreement to which the Controlled Non-Debtor Entity is a party with any other Controlled Non-Debtor Entity.

Exhibit E describes any payment, by the Controlled Non-Debtor Entity, of any claims, administrative expenses or professional fees that have been or could be asserted against any Debtor, or the incurrence of any obligation to make such payments, together with the reason for the entity’s payment thereof or incurrence of any obligation with respect thereto.

This *Periodic Report* must be signed by a representative of the trustee or debtor in possession.

Debtor Name Amyris, Inc.Case number 23-11131

The undersigned, having reviewed the *Entity Reports* for each Controlled Non-Debtor Entity, and being familiar with the Debtor's financial affairs, verifies under the penalty of perjury that to the best of his or her knowledge, (i) this *Periodic Report* and the attached *Entity Reports* are complete, accurate, and truthful to the best of his or her knowledge, and (ii) the Debtor did not cause the creation of any entity with actual deliberate intent to evade the requirements of Bankruptcy Rule 2015.3

**For non-individual
Debtors:**

/s/ Han Kieftenbeld

Signature of Authorized Individual

Han Kieftenbeld

Printed name of Authorized Individual

Date 11/15/2023

MM / DD / YYYY

For individual Debtors:

Signature of Debtor 1

Signature of Debtor 2

Printed name of Debtor 1

Printed name of Debtor 2

Date

MM / DD / YYYY

Date

MM / DD / YYYY



In re: Amyris, Inc. et al.


Case Number:

23-11131 (TMH)

Non-Debtor Entities

<u>Name of Non-Debtor Entity</u>	<u>Interest of the Estate on 9/30</u>
Amyris Bio Products Portugal, Unipessoal, Lda	100%
Amyris Biotecnologia do Brasil Ltda	100%
Amyris Clean Beauty Latam	100%
Amyris Europe Trading B.V.	100%
Amyris Fermentacao de Performance Ltda	69%
Amyris Purificacao de Performance do Brasil Ltda	100% See Note 1
Amyris Realsweet, LLC	69%
Amyris UK Trading Limited	100%
Beauty Labs International Limited	100%
Ecofab, LLC	70%
MG Empower Limited	100%
Accessbio LLC	50% See Note 1
AMF Low Carbon, LLC	40% See Note 1
Amyris Eco-Fab LLC	100% See Note 1
DIPA Co., LLC	100% See Note 1
Interfaces Industria e Comercio de Cosméticos Ltda	100%
Total Amyris Biosolutions BV	25% See Note 1

Note 1 - This Periodic Report does not include information on certain holding companies or pass through entities.



In re: Amyris, Inc et al.

Case Number: 23-11131 (TMH)
Reporting Period: 1/1/2023 - 9/30/2023

Exhibit A-1: Balance Sheet Sep-23											
	Amyris Biotecnologia do Brasil Ltda	Amyris Bio Products Portugal, Unipessoal, Lda	Amyris Fermentacao de Performance Ltda	Amyris Realsweet, LLC	Amyris Clean Beauty Latam	MG Empower Limited	Beauty Labs International Limited	Ecofab, LLC	Interfaces Industria e Comercio de Cosmeticos Ltda	Amyris UK Trading Limited	Amyris Europe Trading B.V.
\$ in actuals											
Cash and cash equivalents	805,571	412,499	1,137,309	-	826,197	-	512,489	-	(58,682)	320,997	10,885
Restricted cash	-	-	-	-	-	-	-	-	-	-	-
Short-term investments	613,674	-	1,991,766	-	1,126	-	-	-	-	-	-
Accounts receivable, net	2,215,610	220,422	750,068	-	891,483	-	7,714,277	-	831,354	1,009,567	-
Contract assets	-	-	6,720,079	-	-	-	-	-	-	705,093	-
Inventories	791,729	723,915	22,637,895	-	824,929	-	-	-	5,289,267	1,051,006	170,491
Deferred cost of revenue	-	-	-	-	-	-	-	-	-	-	-
Prepaid expenses and other current asset	2,345,071	2,915,548	17,177,577	-	4,301,666	-	(64,179)	-	2,066,092	889,437	-
Total current assets	6,771,655	4,272,384	50,414,693	-	6,845,400	-	8,162,588	-	8,128,031	3,976,100	181,376
Property, plant and equipment, net	10,753,087	921,127	143,275,774	-	569,065	-	16,204	-	1,704,489	-	-
Restricted cash, non-current	-	-	-	-	-	-	-	-	-	-	-
Intercompany	11,318,244	(4,363,929)	(21,106,612)	(105,581,662)	(11,677,975)	-	(89,046,817)	-	(13,077,292)	(3,049,313)	(181,376)
Equity and loans in affiliates	-	-	-	-	-	-	-	-	-	-	-
Other assets, non-current	16,159,868	-	13,287,383	-	2,032	-	-	-	46,371	-	-
Investment in Subsidiaries	-	-	-	-	-	-	-	-	-	-	-
Goodwill, Intangible assets,net	455,401	-	-	-	4,191,629	-	15,973,724	-	5,458,839	-	-
Total assets	45,458,255	829,582	185,871,238	(105,581,662)	(69,849)	-	(64,894,300)	-	2,260,439	926,788	-
Trade AP	(711,078)	542	(14,351,174)	-	(5,806,590)	-	-	-	(1,094,847)	(19,445)	-
Accrued AP	(69,994)	(956,919)	(497,546)	-	(368,598)	-	(417,519)	-	(2,943)	(612,872)	-
Other AP	(108)	-	43,373	-	(2,840)	-	-	-	(276)	-	-
Accounts payable	(781,180)	(956,377)	(14,805,347)	-	(6,178,029)	-	(417,519)	-	(1,098,066)	(632,317)	-
Accrued and other current liabilities	(6,626,272)	(418,659)	(1,623,116)	-	(55,579)	-	(1,206,183)	-	(122,799)	(517,956)	-
Capital lease obligation current portion	(109,219)	(77,126)	-	-	-	-	-	-	(36,792)	-	-
Contract liability, current portion	-	37,749	-	-	-	-	-	-	-	-	-
Debt, current portion	(960)	(1,009,654)	2,585	-	(2,425,411)	-	(1,989,712)	-	1,503	-	-
Accrued taxes	-	-	-	-	-	-	-	-	-	-	-
Total current liabilities	(7,517,631)	(2,424,068)	(16,425,878)	-	(8,659,019)	-	(3,613,413)	-	(1,256,155)	(1,150,273)	-
Deferred revenue long-term	-	-	-	-	-	-	-	-	-	-	-
Capital lease obligation, net of current	(21,834)	(26)	(918,354)	-	-	-	3	-	(52,045)	-	-
Long-term debt, net of current	-	-	-	-	-	-	-	-	-	-	-
Derivative liabilities, net of current	-	-	-	-	-	-	-	-	-	-	-
Deferred rent, net of current	-	-	-	-	-	-	-	-	-	-	-
Other liabilities, non current	(28,698)	28,047	-	-	-	-	(265,805)	-	-	-	-
Total liabilities	(7,568,164)	(2,396,047)	(17,344,232)	-	(8,659,019)	-	(3,879,216)	-	(1,308,200)	(1,150,273)	-
Common stock	(100,038,981)	(5,841)	(146,950,734)	(63,740,000)	(4,250,271)	(43)	-	-	(4,168,818)	-	-
Additional paid-in capital, common stock	-	(11,554,119)	(22,774,861)	169,200,537	-	(584,356)	-	-	-	-	-
Accumulated other comprehensive income	23,263,131	300,648	(3,609,734)	-	88,063	-	10,553,494	-	512,558	730,523	-
Previous year retained earnings	36,975,030	9,231,182	1,821,607	121,125	8,081,091	9,273,549	(2,375,788)	7,515,949	901,349	863,814	-
Current year earnings	1,910,728	3,594,595	2,986,716	-	4,809,985	(8,689,151)	60,595,810	(7,515,949)	1,802,673	(1,370,852)	-
Non controlling interest	-	-	-	-	-	-	-	-	-	-	-
Total stockholders' deficit	(37,890,092)	1,566,465	(168,527,006)	105,581,662	8,728,868	-	68,773,516	0	(952,239)	223,486	-
Total liab., min. interest, conv. pref.	(45,458,255)	(829,582)	(185,871,238)	105,581,662	69,849	-	64,894,300	0	(2,260,439)	(926,788)	-

In re: Amyris, Inc et al.

Case Number: 23-11131 (TMH)
Reporting Period: 1/1/2023 - 9/30/2023

Exhibit A-1: Balance Sheet Dec-22											
	Amyris Biotecnologia do Brasil Ltda	Amyris Bio Products Portugal, Unipessoal, Lda	Amyris Fermentacao de Performance Ltda	Amyris Realsweet, LLC	Amyris Clean Beauty Latam	MG Empower Limited	Beauty Labs International Limited	Ecofab, LLC	Interfaces Industria e Comercio de Cosmeticos Ltda	Amyris UK Trading Limited	Amyris Europe Trading B.V.
\$ in actuals											
Cash and cash equivalents	275,219	378,383	325,094	7,415	50,021	80,731	792,710	(175,010)	69,787	-	-
Restricted cash	-	-	-	-	-	-	-	-	-	-	-
Short-term investments	209,887	-	4,865	-	-	-	-	-	-	-	-
Accounts receivable, net	516,398	326,707	(72,431)	-	2,524,940	4,996,087	5,642,441	20	508,496	8,802	-
Contract assets	-	-	-	-	-	-	-	21,252	-	164,519	-
Inventories	736,398	131,891	9,143,640	-	445,713	-	-	4,921,594	850,363	1,423,513	-
Deferred cost of revenue	-	-	-	-	-	-	-	-	-	-	-
Prepaid expenses and other current asset	1,198,756	2,842,429	1,940,682	-	938,978	6,784,827	238,655	571,949	583,065	3,093	-
Total current assets	2,936,658	3,679,410	11,341,850	7,415	3,959,652	11,861,645	6,673,805	5,339,806	2,011,711	1,599,927	-
Property, plant and equipment, net	11,324,851	1,027,712	134,577,377	-	744,118	2,197,301	51,478	-	1,461,768	-	-
Restricted cash, non-current	-	-	-	-	-	-	-	-	-	-	-
Intercompany	17,013,544	(59,396)	20,999,108	(58,003,000)	471,351	(25,262,478)	(83,066,964)	(18,519,071)	(9,571,991)	(2,142,416)	-
Equity and loans in affiliates	-	-	-	-	-	-	-	-	-	-	-
Other assets, non-current	16,489,713	-	13,017,589	-	-	1,112,638	-	-	32,488	-	-
Investment in Subsidiaries	-	-	-	-	-	-	-	-	-	-	-
Goodwill, Intangible assets,net	465,776	-	-	-	-	13,610,109	101,338,161	9,330,557	5,239,029	-	-
Total assets	48,230,543	4,647,726	179,935,924	(57,995,585)	5,175,121	3,519,216	24,996,481	(3,848,707)	(826,995)	(542,489)	-
Trade AP	(2,814,312)	(56,861)	(34,851,909)	-	(4,017,708)	-	-	-	(591,518)	-	-
Accrued AP	(185,054)	(1,144,957)	(646,210)	-	(494,095)	(4,195,101)	(926,340)	(3,663,069)	(3,662)	(252,114)	-
Other AP	682	-	(43,409)	-	(1,515)	-	-	-	-	-	-
Accounts payable	(2,998,683)	(1,201,818)	(35,541,527)	-	(4,513,317)	(4,195,101)	(926,340)	(3,663,069)	(595,180)	(252,114)	-
Accrued and other current liabilities	(5,857,195)	(368,594)	(552,640)	-	(365,232)	77,755	(650,098)	(2,460)	(88,316)	(27,121)	-
Capital lease obligation current portion	(83,610)	(357,951)	-	-	(11,596)	-	(26,502)	-	(29,150)	-	-
Contract liability, current portion	-	38,210	-	-	-	-	-	-	-	-	-
Debt, current portion	(958,211)	(707,528)	-	-	(2,465,697)	(487,330)	(4,729,154)	-	(280)	-	-
Accrued taxes	-	-	-	-	-	-	-	(1,713)	-	-	-
Total current liabilities	(9,897,700)	(2,597,682)	(36,094,167)	-	(7,355,842)	(4,604,676)	(6,332,094)	(3,667,242)	(712,925)	(279,235)	-
Deferred revenue long-term	-	-	-	-	-	-	-	-	-	-	-
Capital lease obligation, net of current	(102,028)	(39,742)	(832,820)	-	-	(6,049,762)	3	-	(77,260)	-	-
Long-term debt, net of current	-	-	-	-	-	-	-	-	-	-	-
Derivative liabilities, net of current	-	-	-	-	-	-	-	-	-	-	-
Deferred rent, net of current	-	-	-	-	-	-	-	-	-	-	-
Other liabilities, non current	(114,523)	28,389	-	-	(1,232,836)	(4,070,932)	(29,719,199)	-	-	-	-
Total liabilities	(10,114,250)	(2,609,035)	(36,926,986)	-	(8,588,678)	(14,725,371)	(36,051,290)	(3,667,242)	(790,186)	(279,235)	-
Common stock	(100,038,981)	(5,841)	(80,930,318)	(63,740,000)	(4,250,271)	-	-	-	-	-	-
Additional paid-in capital, common stock	-	(11,554,119)	(65,275,278)	121,614,460	-	-	-	-	-	-	-
Accumulated other comprehensive income	24,947,658	290,087	1,375,051	-	(417,263)	1,932,606	13,430,597	-	715,831	(42,090)	-
Previous year retained earnings	32,047,281	4,485,931	486,646	(52,747)	3,451,726	195,301	1,386,202	127,349	-	-	-
Current year earnings	4,927,749	4,745,251	1,334,961	173,873	4,629,364	9,078,248	(3,761,990)	7,388,599	901,349	863,814	-
Non controlling interest	-	-	-	-	-	-	-	-	-	-	-
Total stockholders' deficit	(38,116,292)	(2,038,691)	(143,008,938)	57,995,585	3,413,557	11,206,155	11,054,809	7,515,949	1,617,180	821,724	-
Total lib., min. interest, conv. pref.	(48,230,543)	(4,647,726)	(179,935,924)	57,995,585	(5,175,121)	(3,519,216)	(24,996,481)	3,848,707	826,995	542,489	-

In re: Amyris, Inc et al.

Case Number:
Reporting Period:23-11131 (TMH)
1/1/2023 - 9/30/2023

Exhibit A-2: Statement of Operations YTD Sep-23											
	Amyris Biotecnologia do Brasil Ltda	Amyris Bio Products Portugal, Unipessoal, Lda	Amyris Fermentacao de Performance Ltda	Amyris Realsweet, LLC	Amyris Clean Beauty Latam	MG Empower Limited ¹	Beauty Labs International Limited	Ecofab, LLC ²	Interfaces Industria e Comercio de Cosmeticos Ltda	Amyris UK Trading Limited	Amyris Europe Trading B.V.
\$ in actuals											
Total revenue	248	1,316,145	57,377,252	-	23,067	2,812,547	2,031,291	40,560	1,802,148	2,417,160	-
Cost of products sold	500,683	587,709	56,456,752	-	568,734	4,036,256	-	6,698,740	3,289,829	1,367,386	-
Research and development	549,332	2,445,773	132	-		513,154	963,296	-	68,131	-	-
Sales, general and administrative	397,077	1,745,431	962,752	-	3,909,283	3,187,665	63,565,638	11,795,949	148,434	2,560,616	-
Restructuring costs	-	-	-	-		179,593	-	741,274	-	-	-
Total operating expenses	946,409	4,191,203	962,884	-	3,909,283	3,880,412	64,528,934	12,537,222	216,565	2,560,616	-
Total costs and expenses	1,447,092	4,778,913	57,419,636	-	4,478,017	7,916,668	64,528,934	19,235,962	3,506,395	3,928,002	-
Loss from operations	(1,446,843)	(3,462,767)	(42,384)	-	(4,454,950)	(5,104,121)	(62,497,643)	(19,195,402)	(1,704,246)	(1,510,842)	-
Other (income) expense	463,884	129,537	2,943,723	-	355,035	(13,793,272)	(414,203)	(26,711,351)	98,427	(2,881,694)	-
Loss before inc taxes & min interest	(1,910,728)	(3,592,304)	(2,986,107)	-	(4,809,985)	8,689,151	(62,083,440)	7,515,949	(1,802,673)	1,370,852	-
Income taxes	-	2,291	-	-			(1,487,631)	-	-	-	-
Minority interest	-	-	-	-							-
Net gain/(loss)	(1,910,728)	(3,594,595)	(2,986,107)	-	(4,809,985)	8,689,151	(60,595,810)	7,515,949	(1,802,673)	1,370,852	-

¹ Ecofab, LLC entity reflects a positive amount relating to restructuring expense due to the net impact of intercompany elimination as a result of the entity sale during the period.² MG Empower Limited entity reflects a positive amount relating to restructuring expense due to the net impact of intercompany elimination as a result of the entity dissolution during the period.

In re: Amyris, Inc et al.

Case Number: 23-11131 (TMH)
Reporting Period: 1/1/2023 - 9/30/2023

Exhibit A-2: Statement of Operations for the year ended December 31, 2022										
	Amyris Biotecnologia do Brasil Ltda	Amyris Bio Products Portugal, Unipessoal, Lda	Amyris Fermentacao de Performance Ltda	Amyris Realsweet, LLC	Amyris Clean Beauty Latam	MG Empower Limited	Beauty Labs International Limited	Ecofab, LLC	Interfaces Industria e Comercio de Cosmeticos Ltda	Amyris UK Trading Limited
\$ in actuals										
Total revenue	19,685,666	902,712	37,148,401	-	2,578,557	8,560,432	5,757,249	22,005	577,435	135,535
Cost of products sold	15,309,786	262,942	36,775,125	-	2,420,249	8,321,508	3,046	(1,117,599)	1,127,673	156,281
Research and development	2,742,699	2,694,908	(7,806)	-	-	-	3,474,804	-	20,077	-
Sales, general and administrative	5,225,200	2,586,964	482,182	1,054	4,784,632	9,938,582	25,298	8,528,203	-	843,069
Restructuring costs	-	-	-	-	-	-	-	-	-	-
Total operating expenses	7,967,898	5,281,873	474,376	1,054	4,784,632	9,938,582	3,500,102	8,528,203	20,077	843,069
Total costs and expenses	23,277,684	5,544,814	37,249,502	1,054	7,204,881	18,260,090	3,503,148	7,410,604	1,147,750	999,350
Loss from operations	(3,592,018)	(4,642,102)	(101,101)	(1,054)	(4,626,325)	(9,699,658)	2,254,101	(7,388,599)	(570,315)	(863,814)
Other (income) expense	1,335,731	103,149	1,233,815	172,818	3,040	69,394	17,878	-	326,938	-
Loss before inc taxes & min interest	(4,927,749)	(4,745,251)	(1,334,916)	(173,873)	(4,629,364)	(9,769,052)	2,236,223	(7,388,599)	(897,253)	(863,814)
Income taxes	-	-	46	-	-	(690,804)	(1,525,766)	-	4,096	-
Minority interest	-	-	-	-	-	-	-	-	-	-
Net gain/(loss)	(4,927,749)	(4,745,251)	(1,334,961)	(173,873)	(4,629,364)	(9,078,248)	3,761,990	(7,388,599)	(901,349)	(863,814)

In re: Amyris, Inc. et al.

Case Number:

23-11131 (TMH)

Exhibit A-3: Statement of Cash Flows

Statements of cash flows are not prepared for each Controlled Non-Debtor Entity but rather only at the Amyris, Inc. consolidated level. It would be unduly burdensome and costly for the Debtors to prepare these statements for each Controlled Non-Debtor Entity; therefore, these statements have been excluded from this filing.

In re: Amyris, Inc. et al.

Case Number:

23-11131 (TMH)

Exhibit A-4: Statement of Changes in Shareholders' Equity (Deficit)

Statements of changes in shareholders' equity are not prepared for each Controlled Non-Debtor Entity but rather only at the Amyris, Inc. consolidated level. It would be unduly burdensome and costly for the Debtors to prepare these statements for each Controlled Non-Debtor Entity; therefore, these statements have been excluded from this filing.

In re: Amyris, Inc. et al.

Case Number:

23-11131 (TMH)

Exhibit B: Description of Operations

Name of Non-Debtor Entity	Description
Amyris Bio Products Portugal, Unipessoal, Lda	Operates as an international subsidiary of Amyris, Inc.
Amyris Biotecnologia do Brasil Ltda	Operates as an international subsidiary of Amyris, Inc.
Amyris Clean Beauty Latam	Operates as an international subsidiary of Amyris, Inc.
Amyris Europe Trading B.V.	Operates as an international subsidiary of Amyris, Inc.
Amyris Fermentacao de Performance Ltda	Operates as an international subsidiary of Amyris, Inc.
Amyris Purificacao de Performance do Brasil Ltda	Operates as an international subsidiary of Amyris, Inc.
Amyris Realsweet, LLC	Operates as an international subsidiary of Amyris, Inc., Joint venture entity
Amyris UK Trading Limited	Operates as an international subsidiary of Amyris, Inc.
Beauty Labs International Limited	Operates as an international subsidiary of Amyris, Inc.
Ecofab, LLC ¹	Manufactures and sells eco-friendly makeup products., Joint venture entity
MG Empower Limited ²	Digital influencer marketing service provider.
Accessbio LLC	Joint venture between Amyris, Inc. and ImmunityBio, Inc.
AMF Low Carbon, LLC	Operates as a domestic subsidiary of Amyris, Inc., Joint venture entity
Amyris Eco-Fab LLC	Holding company for Ecofab, LLC
DIPA Co., LLC	Operates as a domestic subsidiary of Amyris, Inc., Joint venture entity
Interfaces Industria e Comercio de Cosméticos Ltda	Operates as an international subsidiary of Amyris, Inc.
Total Amyris Biosolutions BV	Operates as an international subsidiary of Amyris, Inc.

¹ Ecofab, LLC entity was dissolved during September 2023² MG Empower Limited was transacted for a limited asset sale in August of 2023

In re: Amyris, Inc. et al.

Case Number:

23-11131 (TMH)

Exhibit C: Description of Intercompany Claims

Debtors and Non-Debtors engage in a variety of intercompany transactions as a part of normal operations. The debtors track all funds transfers through their accounting system and can ascertain, trace and account for all intercompany transactions.

The table below provides the intercompany balances between the Non-Debtor entities as of September 30, 2023.

Due from Party	Due to Party	As of Sep'23	Balance Type	Contingent	Unliquidated	Disputed
Amyris Clean Beauty Latam	Interfaces Industria e Comercio de Cosméticos Ltda	7,413,489	Intercompany Loan			
Interfaces Industria e Comercio de Cosméticos Ltda	Amyris Clean Beauty Latam	(7,413,489)	Intercompany Loan			
Amyris Clean Beauty Latam	Interfaces Industria e Comercio de Cosméticos Ltda	4,522,492	Intercompany Sales			
Interfaces Industria e Comercio de Cosméticos Ltda	Amyris Clean Beauty Latam	(4,569,976)	Intercompany Sales			
Interfaces Industria e Comercio de Cosméticos Ltda	Amyris Clean Beauty Latam	1,153,584	Intercompany Sales			
Amyris Clean Beauty Latam	Interfaces Industria e Comercio de Cosméticos Ltda	(1,153,584)	Intercompany Sales			
Amyris Biotecnologia do Brasil Ltda	Amyris Fermentacao de Performance Ltda	6,467,144	Intercompany Sales			
Amyris Fermentacao de Performance Ltda	Amyris Biotecnologia do Brasil Ltda	(6,467,144)	Intercompany Sales			
Amyris Fermentacao de Performance Ltda	Amyris Biotecnologia do Brasil Ltda	-	Intercompany Sales			
Amyris Biotecnologia do Brasil Ltda	Amyris Fermentacao de Performance Ltda	(134,705)	Intercompany Sales			
Interfaces Industria e Comercio de Cosméticos Ltda	Amyris Bio Products Portugal, Unipessoal, Lda	170,491	Intercompany Sales			
Amyris Bio Products Portugal, Unipessoal, Lda	Interfaces Industria e Comercio de Cosméticos Ltda	-	Intercompany Sales			
Beauty Labs International Limited	Amyris UK Trading Limited	3,646,915	Intercompany Sales			
Amyris UK Trading Limited	Beauty Labs International Limited	(3,626,342)	Intercompany Sales			
Amyris Bio Products Portugal, Unipessoal, Lda	Amyris Europe Trading B.V.	-	Intercompany Sales			
Amyris Europe Trading B.V.	Amyris Bio Products Portugal, Unipessoal, Lda	(170,491)	Intercompany Sales			
Amyris Biotecnologia do Brasil Ltda	Interfaces Industria e Comercio de Cosméticos Ltda	279,766	Intercompany Sales			
Interfaces Industria e Comercio de Cosméticos Ltda	Amyris Biotecnologia do Brasil Ltda	(279,766)	Intercompany Sales			
Amyris Bio Products Portugal, Unipessoal, Lda	Amyris UK Trading Limited	81,732	Intercompany Sales			
Amyris UK Trading Limited	Amyris Bio Products Portugal, Unipessoal, Lda	(60,674)	Intercompany Sales			

In re: Amyris, Inc. et al.

Case Number:

23-11131 (TMH)

Exhibit D: Allocation of Tax Liabilities and Assets

No tax payments, refunds or attributes have been allocated to the Controlled Non-Debtor entities. The tax accounts included in the financial statements of the Controlled Non-Debtor entities represent each individual entity's results without allocations.

There are currently no tax sharing or tax allocation agreements to which any Controlled Non-Debtor entity is a party.

In re: Amyris, Inc. et al.

Case Number:

23-11131 (TMH)

**Exhibit E: Description of Controlled Non-Debtor Entity's payments of Administrative Expenses, or Professional Fees
otherwise payable by a Debtor**

As of the balance sheet date of the financials presented in Exhibit A, no payment of administrative expenses, professional fees, or otherwise were paid by the Controlled Non-Debtor Entities that would have otherwise been payable by a Debtor Entity. From time to time, a Controlled Non-Debtor will pay for services that may benefit both Debtor and Non-Debtor entities, however, those services are obligations of the Controlled Non-Debtor.